Eylea is a new anti growth factor agent injected into the vitreous cavity in the same way as Lucentis. Recent trials have shown Eylea to be as effective as Lucentis in the treatment of age related macular degeneration but with the advantage of only requiring review and re treatment every 2 months.
For further information on this new development please follow link below.